Ovarian Cancer Metastasis: A Unique Mechanism of Dissemination by Mitra, Anirban K.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Ovarian Cancer Metastasis: A Unique Mechanism of
Dissemination
Anirban K. Mitra
Additional information is available at the end of the chapter
http://dx.doi.org/DOI:10.5772/64700
Abstract
Ovarian cancer is the most lethal of all gynecologic malignancies and has witnessed
minimal improvements in patient outcomes in the past three decades. About 70% of
ovarian cancer patients present with disseminated disease at the time of diagnosis. The
standard of  care  remains  a  combination  of  debulking  surgery  and platinum‐  and
taxanes‐based cytotoxic chemotherapy. Even though metastasis is the leading cause of
ovarian cancer related fatalities, our understanding of the process remains limited.
Ovarian cancer has a unique pattern of metastasis where the hematogenous spread is
less common. Ovarian cancer cells mainly metastasize within the peritoneal cavity,
which involves exfoliation from the primary tumor,  survival,  and transport in the
peritoneal fluid followed by metastatic colonization of the organs within the perito‐
neal cavity. A key step for successful metastasis is their attachment and productive
interactions with the mesothelial cells covering the metastatic organs for the establish‐
ment  of  metastatic  tumors.  This  chapter  provides  an  overview  of  ovarian  cancer
metastasis highlighting the unique dissemination and the underlying mechanisms of
regulation of the steps involved. The role of the microenvironment in the process of
metastasis will also be reviewed.
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1. Introduction
Ovarian cancer is the most lethal of all gynecologic malignancies. It accounts for a fifth of all
cancer‐related deaths among women in the United States of America. It is estimated that 22,280
women will be diagnosed with ovarian cancer and 14,240 will die of the disease in the United
States in 2016 [1]. This makes it a relatively less prevalent but a very deadly form of cancer. About
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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90% of all ovarian cancers are epithelial in origin, which are classified into high‐grade serous,
low‐grade serous, endometrioid, clear cell, and mucinous subtypes [2]. Of these, the high‐
grade serous ovarian cancer (HGSOC) is the most common subtype and is characterized by
mutations in p53 and genomic instability [3]. A detailed characterization of the HGSOC tumors
was done by The Cancer Genome Atlas Network, which mapped the deregulated pathways
involved. In the past, these tumors were thought to originate from the ovarian surface epithe‐
lium. However, more recently researchers have started to believe that they may actually originate
from the fallopian tube fimbriae based on the analysis of prophylactic salpingo‐oophorecto‐
my samples [4].
One of the reasons for the poor prognosis of ovarian cancer is the fact that most patients are
diagnosed late [5]. It is a highly metastatic cancer and more than 70% of ovarian cancer patients
are diagnosed with metastasis [6]. As the tumor grows within the peritoneal cavity, the
symptoms produced are abdominal pain or bloating and may be confused with other bowel
diseases like irritable bowel syndrome [7, 8]. Ovarian cancer is often called ‘the silent cancer’
or ‘the disease that whispers’ because of these diffuse symptoms. The presence of high levels
of cancer antigen 125 (CA‐125) is used as a diagnostic marker of disease progression. Pelvic
ultrasound, MRI, and CT scanning is also used to determine the extent of the disease. Patients
undergo a ‘debulking’ surgery usually conducted by a gynecologic oncologist with a goal to
remove as much of the tumor masses as possible from the abdomen [9]. In addition, the tumors
are also staged histopathologically as per the International Federation of Gynecology and
Obstetrics (FIGO) guidelines (Table 1) [10]. Minimal residual disease after the surgery is
considered one of the strongest prognostic factors and is highly desirable [11]. The surgery is
followed by adjuvant cytotoxic chemotherapy consisting of a combination of carboplatin and
paclitaxel. The response to therapy is determined by measuring the serum CA‐125 levels and
by imaging techniques [2]. If the disease relapses within 6 months, it is considered chemore‐
sistant and if relapse occurs after 12 months, it is considered chemosensitive. While a majority
of the patients respond well initially to chemotherapy, most eventually end up developing
chemoresistance [12]. Bowel obstruction by the metastatic tumors is the predominant cause of
ovarian cancer‐related mortality [13]. Since many parts of the bowel get affected, it becomes
extremely difficult to surgically treat this condition. In addition, extensive ascites is a cause for
major discomfort. Palliative measures such as control of nausea, abdominal pain, draining
ascites, and modified diet are typically resorted to [2]. Since most of the ovarian cancer patients
are diagnosed with advanced disease, in effect, it is metastasis that is being treated [6].
Therefore, a greater understanding of the process and regulation of ovarian cancer metastasis
is essential.
Ovarian cancer predominantly metastasizes within the peritoneal cavity and through the
pelvic lymph nodes (Figure 1) [14, 15]. However, recent evidence suggests the possibility of
hematogenous metastasis of ovarian cancer (Figure 1) [16]. This chapter will discuss the steps
involved in the unique metastatic dissemination of ovarian cancer and will highlight what is
known about the regulation of the steps involved.
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Stage I: The disease limited to ovaries only
 • Ia: Tumor in only one ovary or fallopian tube with intact capsule
 • Ib: Tumor in both the ovaries
 • Ic: Tumor on the surface of one or both ovaries/fallopian tubes with ruptured capsule and cancer cells present in
peritoneal washings
Stage II: Tumors spread to the pelvis but limited to below the pelvic brim
 • IIa: Tumors spread to the fallopian tubes or uterus or both
 • IIb: Tumors spread to other pelvic tissues within the peritoneum
Stage III: Tumors have spread to the abdomen beyond the pelvis or has metastasized to the lymph nodes or both
 • IIIa: Microscopic involvement of extra pelvic peritoneal regions
 • IIIb: Tumors up to 2 cm diameter
 • IIIc: Disease greater than 2 cm with or without lymph node involvement
Stage IV: Distant metastases: pleural effusions contain cancer cells and metastasis to the liver and spleen parenchyma
Table 1. International Federation of Gynecology and Obstetrics staging of ovarian cancer [10].
Figure 1. Mechanisms of ovarian cancer metastasis: Transcoelomic dissemination. (1) The cancer cells loose cell–cell
contact and exfoliate into the peritoneal cavity. (2) They float in the peritoneal fluid and are carried all over the perito‐
neal cavity. (3) Attachment to the peritoneal organs like the omentum. (4) Formation of the metastatic tumor. Hema‐
togenous metastasis. (A) Invasion and intravasation. (B) Transport of circulating cancer cells through the blood vessels.
(C) Extravasation from the omental capillaries. (D) Formation of the metastatic tumor in the omentum.
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2. Overview of ovarian cancer metastasis
The lack of an anatomic barrier allows the ovarian cancer cells to very conveniently spread
into the peritoneal cavity. The cancer cells on the surface of the primary tumors start loosing
cell–cell contact and become loosely attached to each other. As a result of this, they become
prone to exfoliation into the peritoneal cavity (Figure 1). Exfoliation is promoted by the
mechanical forces like rubbing of neighboring peritoneal organs during respiratory move‐
ments and flow of the peritoneal fluids. The cancer cells may come off as single cells or as
clumps. This is a passive mode of dissemination unlike the typical invasion followed by
intravasation observed in tumors undergoing hematogenous metastasis [13, 17, 18]. The
peritoneal fluid naturally flows within the peritoneal cavity upward, toward the head, and
then back downward, toward the feet, as a result of the diaphragm movement during
respiration and gravitational pull, respectively [19]. The exfoliated ovarian cancer cells from
the primary tumor are disseminated throughout the peritoneal cavity by this natural flow of
the peritoneal fluid (Figure 1). Since normally there is only a small volume of the peritoneal
fluid present, dissemination is predominantly limited to the organs in the vicinity of the
primary tumor [17]. As the disease progresses, more and more ascites is produced and this
enables the spread of the cancer cells to more distant sites in the abdomen. One of the pre‐
dominant sites of ovarian cancer metastasis is the omentum which is a fatty double fold of the
peritoneal membrane, about 8 by 8 inches in size, covering the bowels [13]. It is important to
note that this mode of spreading typical of ovarian cancer is very different in terms of the
hydrodynamic forces experienced by the cancer cells when they are carried rapidly in the blood
vessels during hematogenous metastasis [20, 21].
Epithelial cells tend to undergo anoikis in the absence of attachment to a substratum. Therefore,
the main challenge faced by the cancer cells floating in the peritoneal fluid is overcoming
anoikis and surviving floatation. In addition, they have to avoid immune surveillance. The
cancer cells either form aggregates or spheroids or exist as single cells (Figure 1) [22]. The
spheroids may also contain embedded cancer‐associated fibroblasts as well as activated
mesothelial cells, which contribute to the development of the ascetic microenvironment [22].
The subsequent challenge for these floating cancer cells is to successfully attach to the surface
of the organs in the peritoneal cavity (Figure 1). Debulking surgery often reveals such
spheroids loosely attached to the peritoneum. The mesothelial cells covering the peritoneum
and the bowels secrete mucus like substances, which help in reducing friction between surfaces
as they brush against each other during the course of the organs’ natural movements. The same
also helps in preventing attachment of the cancer cells to some extent. However, the integrins
expressed by the metastasizing cells help them to attach to the extra cellular matrix proteins
(ECMs) secreted by the mesothelial cells. Thereafter, the cancer cells are able to push apart the
mesothelial cells forming the protective barrier and invade into the organ [23, 24].
Having invaded through the mesothelium of the site of metastasis, the cancer cells have to
now revert back to their normal self of growing attached to a substratum. However, since they
are now encountering a new microenvironment with a potentially different ECM and secreted
factors, they have to now adapt to these new conditions. The adaptive process involves
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extensive and productive reciprocal interactions between the cancer cells and the normal
microenvironment of the metastatic site [6]. Those cells, which are able to successfully adapt
to this new microenvironment, go on to eventually establish metastatic colonies. On the other
hand, the cells that cannot productively interact and adjust to the new microenvironment
eventually perish or remain dormant. The cells that are successful eventually reprogram the
microenvironment to form and ‘activated tumor stroma,’ which include cancer‐associated
fibroblasts, endothelial cells, immune cells, and modified ECMs that promote tumor growth
at the metastatic site. In addition to the peritoneal dissemination described above, ovarian
cancer cells have been found in blood circulation and recent reports have indicated the
existence of an alternative hematogenous mode of metastasis [16, 25].
The process of attaching to and developing metastatic tumors in the new organ is known as
metastatic colonization (Figure 1). It is considered the least efficient step in the whole process
of metastasis [21, 26]. This is also evidenced in mouse xenograft experiments to study ovarian
cancer metastasis where many millions of cancer cells are injected intraperitoneally and result
in about a hundred tumors or even less [6, 27, 28]. At the same time, the mechanism of
regulation of this step and the initial cross talk between the cancer cells and the microenvir‐
onment remains a mystery for the obvious difficulty in getting access to this window. Greater
understanding of the biology of this process will enable the identification of key regulators
that can be targeted therapeutically to hit the metastatic disease at its most vulnerable phase.
3. Mechanism of peritoneal metastasis
The first step in the peritoneal metastasis is exfoliation of the ovarian cancer cells from the
primary tumor into the peritoneal cavity. The prerequisite for this step is the loss of cell–cell
contact between the cancer cells. As mentioned earlier, ovarian cancer can potentially arise
from the fallopian tube epithelial cells or ovarian surface epithelium. Both express the classic
epithelial marker epithelial cadherin (E‐cadherin) [29]. E‐cadherin plays a key role in epithelial
cell behavior, tumor suppression, and tissue architecture through its function as a cell–cell
adhesion molecule [30]. It is associated with the actin cytoskeleton through α, β, and γ catenins.
While E‐cadherin is directly involved in the formation of adherens junctions between adjacent
epithelial cells, it can also regulate the formation of tight junctions and desmosomes [30, 31].
As the cancer progresses from a benign to a malignant form, the cells undergo an epithelial to
mesenchymal transition (EMT). This involves molecular and morphological changes wherein
they loose their epithelial characteristics and gain mesenchymal traits. This includes a loss of
the compact cell‐to‐cell attachment, polarity, and cuboidal shape. The cells become more
spindle shaped and motile. EMT also involves a change in the expression of epithelial and
mesenchymal markers [32]. A very important aspect of this transition is the loss of expression
of E‐cadherin and a concomitant increase in the expression of neural cadherin (N‐cadherin).
This results in a reduction in the cell–cell interaction between cancer cells through their
adherens junctions and an increase in the ability of the cancer cells to interact with the normal
stromal cells present in the microenvironment. In ovarian cancer, E‐cadherin expression can
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be regulated transcriptionally and post‐transcriptionally [33]. ZEB‐1, ZEB‐2, Snail, and Slug
are known to repress E‐cadherin and can be regulated by several external cues. The signaling
pathways that regulate EMT and E‐cadherin expression include transforming growth factor
β (TGF‐β), epidermal growth factor (EGF), hepatocyte growth factor (HGF), endothelin‐1 (ET‐
1), and bone morphogenetic protein 4 (BMP‐4) [32]. Moreover, the miR‐200 family of micro‐
RNAs can also indirectly regulate EMT by targeting ZEB‐1 and ZEB‐2, which results in the
derepression of E‐cadherin [34]. Decreased expression of miR‐200 family resulted in an
increase in the expression of ZEB‐1 and ZEB‐2, which repressed E‐cadherin transcription and
induced EMT in ovarian cancer.
The loss of E‐cadherin expression and the resulting decrease in the cell–cell attachment
promotes the dissemination of the cells into the peritoneal cavity. Interestingly, the loss in E‐
cadherin expression was found to lead to an induction of expression of α5‐integrin [35]. α5‐
integrin forms a heterodimer with β1‐integrin that binds to fibronectin and hence is called the
fibronectin receptor. The induction of α5‐integrin was not through the canonical β‐catenin
pathway. Instead, it was through the epithelial growth factor receptor (EGFR)/focal adhesion
kinase (FAK)/mitogen‐activated protein kinase (MAPK) pathway. The increase in fibronectin
receptor expression was found to help the disseminated ovarian cancer cells attach to the
fibronectin secreted by the mesothelial cells lining the omentum and peritoneum [35]. This is
an evidence of how the loss of E‐cadherin—which facilitates shedding—is coupled to prepar‐
ing the cells to reattach at the distant metastatic site.
Once the cancer cells have been shed into the peritoneal fluid, it significantly affects the
prognosis of the patient as evidenced by the 29% relapse rate of stage 1A ovarian cancer
compared to 59% relapse rate of stage 1C [36]. However, once detached from the tumor mass,
the cancer cells face several challenges in surviving in the peritoneal fluid. The peritoneal fluid
is a result of continuous secretion of fluids by the peritoneal capillaries. This helps in lubricating
the adjacent organs in the peritoneal cavity and allows uptake of soluble factors through the
peritoneum. A majority of the peritoneal fluid is returned to the circulation through lymphatic
drainage. However, in ovarian cancer patients, the increased leakiness of vasculature induced
by high vascular endothelial growth factor (VEGF) levels accompanied by blocking of the
lymphatic vessels by cancer cells results in ascites formation [22]. This ascites is called
malignant ascites because of the presence of floating cancer cells. The malignant ascites
facilitates the spread of the cancer cells throughout the peritoneal cavity.
The disseminated ovarian cancer cells floating in the ascites either as spheroids or as single
cells develop resistance to anoikis and acquire cancer stem cell‐like properties [37, 38].
Interestingly, the single‐cell population was found to have a greater percentage of cancer stem
cells [39]. The cancer stem cells enriched from ascites have highly elevated ability to form
mouse xenograft tumors [40]. Just like cancer stem cells, the floating spheroids and single cells
are resistant to chemotherapy. The compact nature of the spheroids serves as an additional
physical barrier for the chemotherapeutic agents, preventing the inner cells from exposure to
the drug [22]. Taken together, this indicates that the cancer cells floating in the ascites are stem‐
like and chemoresistant and have the potential to seed new metastatic tumors within the
peritoneal cavity.
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The spheroids have elevated levels of E‐cadherin and EpCAM and concomitant diminished
expression of vimentin, matrix metalloproteinases (MMPs), and CD44 [37, 39]. Therefore, the
metastasizing cancer cells demonstrate plasticity in terms of their ability to switch back and
forth from epithelial and mesenchymal phenotypes as per the demands of the different steps
of metastasis. In addition to the cancer cells, the ascites has several normal cell types that
together form the malignant ascites microenvironment and supports the floating cancer cells.
The main non‐cancer‐cell types include cancer‐associated fibroblasts (CAFs), mesothelial cells,
immune cells, mesenchymal stem cells, and platelets [22]. These cells can be associated with
the cancer spheroids or the single cells. They can also exist by themselves, floating in the
peritoneal fluid. These supporting cells produce a milieu of factors that assist the cancer cell
survival and subsequent colonization of the metastatic site. Cells like platelets also offer
protection from immune surveillance by coating the cancer cells.
Having successfully survived flotation in the peritoneal fluids, the next goal of the metasta‐
sizing ovarian cancer cells is to attach to the various organs present in the peritoneal cavity.
Electron micrographs of sections of normal peritoneum and omentum have revealed the
architecture of the mesothelium covering them. The mesothelium consists of a monolayer of
mesothelial cells that are very tightly joined end to end to form a protective barrier [24]. These
mesothelial cells serve to provide a slippery surface—through the secretion of glycosamino‐
glycans and lubricants—facilitating normal coelomic movement as well as preventing
infection and attachment of cancer cells [41]. The mesothelial cells can perform diverse
functions such as secretion of ECMs, growth factors, and inflammatory cytokines for tissue
repair and regeneration, proteases for fibrinolysis, and prevention of adhesions [41]. They are
also actively involved in the movement of fluids and solutes across serosal cavities [42].
Early in vitro experiments revealed that the ovarian cancer cells force the retraction of the
mesothelial cells upon attachment to the mesothelium [43]. More recently, Iwanicki et al. have
demonstrated the role of the fibronectin receptor (α5β1‐integrin) expressed on the surface of
the ovarian cancer cells help them attach to the fibronectin secreted on the surface of the
mesothelial cells and promote the displacement of mesothelial cells through myosin‐mediated
traction forces [24]. Subsequent studies revealed the ovarian cancer cells with a mesenchymal
phenotype had a greater propensity for mesothelial clearance [44]. The fibronectin secretion
by the mesothelial cells was found to be induced by their interaction with the metastasizing
ovarian cancer cells. The TGF‐β secreted by the cancer cells activated a RAC1/SMAD‐mediated
signaling pathway in the mesothelial cells, which resulted in the transcriptional upregulation
of the fibronectin gene and also induced an EMT‐like phenotype in the mesothelial cells [45].
This would probably help in subsequent mesothelial clearance and also may potentially serve
as a source of cancer‐associated fibroblasts in the microenvironment of the metastatic tumor
[46].
The increased expression of the fibronectin receptor in the ovarian cancer cells is also beneficial
in coupling attachment to growth factor signaling to promote metastasis. Inhibition of the
interaction of α5β1‐integrin on the cancer cells with the fibronectin on the surface of the
omentum and peritoneum in mouse xenograft models of ovarian cancer metastasis resulted
in a decreased metastatic burden in both prevention and intervention settings [28]. Since
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inhibition of α5β1‐integrin can also inhibit angiogenesis, it was further investigated whether
the effects on metastasis were actually due to disruption of the human cancer cell α5β1‐integrin
interaction with fibronectin or that of the mouse endothelial cell α5β1‐integrin. The effect of an
anti‐murine α5β1‐integrin‐blocking antibody was compared to that of the anti‐human α5β1‐
integrin‐blocking antibody. Interestingly, the murine‐blocking antibody did not show any
significant effect and, therefore, confirmed the key role of the interactions of the cancer cell
α5β1‐integrin with the fibronectin of the microenvironment in promoting ovarian cancer
metastasis [28]. Further investigation revealed that the activation of α5β1‐integrin resulted in
the activation and phosphorylation of the receptor tyrosine kinase c‐Met independent of its
ligand—hepatocyte growth factor (HGF) [28]. This attachment induced activation of the
growth factor receptor lead to increased invasiveness and growth through the subsequent
activation of the FAK/Src signaling pathways in the cancer cells. The expression of a consti‐
tutively active FAK could abrogate the inhibitory effects of the α5β1‐integrin‐blocking antibody
on the ovarian cancer cells [28].
Another effect of adhesion of the ovarian cancer cells to the surface of the omentum is the
increased secretion of the extracellular protease MMP‐2. It cleaves fibronectin and vitronectin
present on the surface of the mesothelium into smaller fragments, which enhances binding of
the cancer cells to these ECMs through their specific integrin receptors α5β1‐integrin and αvβ3‐
integrin, respectively [47]. Inhibition of MMP‐2 in the ovarian cancer cells as a prevention
measure inhibited their adhesion to the omentum in nude mice. However, the host MMP‐2
did not play a role in this process as evidenced in MMP‐2 knockout mouse xenograft experi‐
ments [47].
Once the cancer cells attach to the mesothelial cells on the surface of the omentum, they embark
on a process of adapting to the new microenvironment of the site of metastasis. As evidenced
by the ECM-cancer cell interactions and their consequences above, more productive reciprocal
interactions between the cancer cells and their new microenvironment are essential for
successful establishment of the metastatic tumors. The cancer cells have to revert from
surviving anoikis while floating in the peritoneal fluid to an attached growth in the presence
of new ECMs and growth factors available in the microenvironment of the omentum and
peritoneum. This involves significant changes in the gene expression profiles of the colonizing
cancer cells and, therefore, would involve the activation/repression of transcriptional/
translational regulators dependent on microenvironmental cues. One such important micro‐
environment regulated translational regulator was reported to be the micro‐RNA miR‐193b [6].
miR‐193b is a tumor suppressor micro‐RNA that was found to be downregulated in the
metastasizing ovarian cancer upon their interaction with the mesothelial cells covering the
surface of the omentum. This downregulation promoted growth and invasiveness of the cancer
cells in vitro, colonization of human omentum ex vivo, and decreased metastasis in mouse
xenografts [6]. Interestingly, the miR‐193b downregulation was induced by the hypermethy‐
lation of its promoter as a result of the cross talk between the cancer cells and the mesothelial
cells. The promoter hypermethylation was catalyzed by the increased expression of DNMT1
in the cancer cells stimulated by their interaction with the mesothelium [6]. miR‐193b was
found to directly target urokinase. A decrease in miR‐193b expression resulted in increased
Tumor Metastasis50
expression of urokinase, which mediated the functional effects of miR‐193b in driving
metastatic colonization of the omentum [6].
As the cancer cells adapt to the new microenvironment of the metastatic site and start to
proliferate, they also recruit resident and non‐resident normal cells and convert them into the
tumor‐associated stroma or ‘activated stroma’ [48]. It is well known that the tumors consist of
10–50% of non‐cancer cells or the tumor stroma [49]. The key components of this tumor stroma
are the cancer‐associated fibroblasts (CAFs), tumor‐associated macrophages (TAMs), and
other immune cells, endothelial cells, pericytes, adipocytes, extracellular matrix proteins, etc.
[50]. All these stromal components are essential for successful growth and progression of the
tumors as they are a critical source of growth and tropic factors, help in evasion of immune
surveillance, angiogenesis, ECM remodeling, invasiveness, etc. Therefore, the eventual success
of the cancer cells in colonizing the omentum will depend upon their ability to develop an
active tumor stroma.
The metastasizing ovarian cancer cells were found to recruit the resident normal fibroblasts in
the basement membrane of the omentum and reprogram them into CAFs. This reprogramming
was driven by the decreased expression of miR‐214, miR‐31, and an increase in the expression
of miR‐155 in the normal fibroblasts induced by the cancer cells [49]. The resulting CAFs
promoted ovarian cancer cell migration, invasion, and colony formation in vitro and tumor
growth and metastasis in vivo. Interestingly, CAFs could be converted back into normal
fibroblasts by the combined overexpression of miR‐214 and miR‐31 and inhibition of miR‐155.
The micro‐RNAs mediated their effects through an array of targets, most of which were
identified as chemokines and cytokines. The main mediator was found to be CCL5, which was
a direct target of miR‐214. Inhibition of CCL5 in nude mice injected with a mixture of ovarian
cancer cells and CAFs significantly decreased the ability of the CAFs to promote tumor growth
and metastasis [49].
An important and abundant cellular component of the omentum is adipocytes. Until recently,
not much was known about the direct role of the omental adipocytes in promoting ovarian
cancer metastasis to the omentum even though it is well established that omentum is one of
the main sites of ovarian cancer metastasis and that it is a predominantly fatty tissue. Dr.
Lengyel’s group went on to demonstrate that the omental adipocytes secrete adipokines that
promote the homing of the metastasizing ovarian cancer cells to the omentum [51]. The cancer
cells, thereafter, could induce metabolic reprogramming of the adipocytes and induce lipolysis
in them. The adipocytes in turn induced the expression of FABP4—a fatty acid transporter—
in the cancer cells. As a result of this, the cancer cells efficiently take up the free fatty acids
released by the adipocytes and utilize them as a source of energy and building blocks to drive
tumor growth [51]. This explains why the omentum tumor is usually the largest one in the
peritoneal cavity with sometimes the whole omentum getting converted into a solid, hard
omental cake. By that time, all the adipocytes have been depleted and used for the growth of
the metastatic tumor.
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4. Other mechanism of dissemination
While the transcoelomic route of peritoneal dissemination is thought to be the predominant
mode of ovarian cancer spread, other mechanisms do exist. The ascites produced in the
peritoneal cavity is typically drained through the lymph vessels present in the diaphragm [36].
This provides the cancer cells present in the ascites, the opportunity to metastasize to the lymph
nodes. Moreover, the lymphatic vessels drain into the left subclavian vein via the thoracic duct.
This enables some cancer cells to enter into the blood circulation.
Although circulating ovarian cancer cells have long been reported to be present in the blood
[52], it has typically been considered a mode of dissemination only in the very late stages of
the disease. The prevalent reasoning being that although the ovarian cancer cells enter into the
circulation, they are not yet adept at surviving in the circulation and establish metastatic
tumors in a very different ‘soil.’ However, recent reports have suggested that hematogenous
metastasis may be more commonly occurring in ovarian cancer that we had thought [16, 53].
Using a parabiosis model, Pradeep et al. have very elegantly demonstrated the haematogenous
metastasis of the ovarian cancer cells from the primary tumor in one mouse to the omentum
of the paired mouse [16]. The expression of ErBB3 in the ovarian cancer cells entering into
circulation and the omental expression of NRG1 was found to be the key players responsible
for the hematogenous metastasis [16]. Interestingly, the use of mouse models of hematogenous
ovarian cancer metastasis revealed a preferential homing of the cancer cells to the ovary
followed by the development of ascites and subsequent peritoneal metastasis [53]. When the
ovaries were removed before injecting the cancer cells, peritoneal metastasis and ascites
formation were completely abolished [53]. Taken together, recent evidences point toward a
more significant role of hematogenous dissemination in ovarian cancer that previously
thought.
5. Conclusion
Ovarian cancer is a malignancy where most patients are treated for metastatic disease because
they are usually diagnosed at an advanced stage. A better understanding of the process of
metastasis and the underlying mechanisms of regulation is crucial for development of effective
therapies. However, our knowledge in this field remains limited. It has become increasingly
clear that there are multiple different ways in which the cancer cells disseminate, and the
transcoelomic rout remains the most predominant mode. While it appears to be a relatively
simpler way to metastasize, the steps involved pose their own unique challenges to the cancer
cells. Moreover, the absence of the need for invasion, intravasation, and extravasation can
potentially enable the cancer cells to metastasize earlier and in greater numbers than in case
of hematogenous metastasis. Studying the underlying mechanisms have remained challenging
but the evolution of in vitro organotypic 3D culture models have opened up opportunities to
conduct more meaningful experiments and have lead to significant leaps in knowledge [6, 24,
45]. Use of ovarian cancer cell lines that closely resemble the mutational profile of clinical
Tumor Metastasis52
HGSOC samples will also contribute toward meaningful progress in research in this field [54,
55]. The use of such models will hopefully provide greater insights into the regulation of
metastatic colonization and enable therapeutic targeting of the disease at the stage in which
they are most vulnerable. Moreover, considering the key roles played by the microenviron‐
ment of the site of metastasis as well as the tumor stroma, these ‘normal’ components can be
targeted as well as the cross talk between them and the cancer cells. Since these cells are
genetically stable and provide multiple different modes of support to the cancer cells, there
will hopefully be reduced chances of development of drug resistance.
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